Opinion|Videos|March 12, 2026
How Selinexor Plus Ruxolitinib Could Affect Frontline Myelofibrosis Management
Author(s)Prithviraj Bose, MD, Pankit Vachhani, MD
Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss how selinexor plus ruxolitinib could affect the frontline myelofibrosis treatment paradigm.
Advertisement
Episodes in this series
Prithviraj Bose, MD, and Pankit Vachhani, MD, explore how positive results from the phase 3 SENTRY trial (NCT04562389) could influence the frontline treatment paradigm for myelofibrosis. Bose discusses the potential for combination therapy with selinexor (Xpovio) plus ruxolitinib (Jakafi) to move beyond symptom control toward disease modification. Vachhani considers patient populations that may derive the greatest benefit and how treatment sequencing strategies could evolve.
Advertisement
Related to this article
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5